See more : Unitronix Corporation (UTRX) Income Statement Analysis – Financial Results
Complete financial analysis of Kraig Biocraft Laboratories, Inc. (KBLB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kraig Biocraft Laboratories, Inc., a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
You may be interested
- Griffon Corporation (GFF) Income Statement Analysis – Financial Results
- Mordovia Energy Retail Company Public Joint-Stock Company (MRSB.ME) Income Statement Analysis – Financial Results
- HYOJITO Co., Ltd. (7368.T) Income Statement Analysis – Financial Results
- Panatlântica S.A. (PATI3.SA) Income Statement Analysis – Financial Results
- Coliseum Acquisition Corp. (MITAW) Income Statement Analysis – Financial Results
Kraig Biocraft Laboratories, Inc. (KBLB)
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. engages in developing protein-based fibers using recombinant DNA technology for commercial applications in the technical textile and specialty fiber industries in the United States. The company's products are used in military and police applications for ballistic protection; industrial applications, including critical cables and abrasion/impact resistant components; safety equipment; and composite materials for the aero-space industry. Its products are also used in various markets, such as medical textiles, geotextiles, defense and military textiles, safe and protective clothing, filtration textiles, composites with textile structure, and functional and sportive textiles, as well as textiles used in buildings and transportation. The company was incorporated in 2006 and is headquartered in Ann Arbor, Michigan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 401.62K | 97.32K | 31.86K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 27.62K | 28.10K | 3.68B | 13.09B | 14.79B | 11.52B | 10.56B | 16.97K | 15.42K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -27.62K | -28.10K | -3.68B | -13.09B | -14.79B | -11.52B | -10.56B | 14.88K | -15.42K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,868,283.05% | -10,850,924.48% | 46.72% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 237.87K | 176.43K | 197.75K | 88.47K | 223.05K | 148.07K | 258.89K | 397.14K | 432.01K | 439.54K | 489.43K | 465.29K | 250.60K | 141.31K | 69.80K | 33.08K | 177.02K | 164.91K |
| General & Administrative | 1.58M | 1.94M | 2.56M | 4.45M | 2.40M | 1.21M | 1.99M | 2.58M | 1.62M | 1.39M | 1.79M | 695.11K | 1.05M | 1.05M | 427.51K | 320.00K | 300.00K | 370.00K |
| Selling & Marketing | 797.41K | 0.00 | 0.00 | 0.00 | 0.00 | -2.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -7.01K | -13.34K | -5.25K |
| SG&A | 2.38M | 1.94M | 2.56M | 4.45M | 2.40M | 1.21M | 1.99M | 2.58M | 1.62M | 1.39M | 1.79M | 695.11K | 1.05M | 1.05M | 427.51K | 312.99K | 286.66K | 364.75K |
| Other Expenses | 0.00 | 779.74B | 734.43B | 516.33B | 627.20B | -1.00 | 2.00 | -4.00 | -2.00 | -4.00 | -5.19M | 3.00K | 598.00 | 93.91K | 27.20K | 12.65K | 6.21K | -5.09K |
| Operating Expenses | 2.61M | 2.12M | 2.76M | 4.53M | 2.62M | 1.36M | 2.25M | 2.98M | 2.05M | 1.83M | 2.28M | 1.16M | 1.30M | 1.29M | 524.71K | 355.65K | 472.86K | 529.67K |
| Cost & Expenses | 2.61M | 2.12M | 2.76M | 4.53M | 2.62M | 1.36M | 2.25M | 2.98M | 2.05M | 1.83M | 2.28M | 1.16M | 1.30M | 1.29M | 524.71K | 355.65K | 472.86K | 529.67K |
| Interest Income | 0.00 | 1.72K | 5.36K | 386.62 | 6.37K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 47.00 | 192.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 375.10K | 609.13K | 660.42K | 386.62K | 294.35K | 228.95K | 177.11K | 139.43K | 101.55K | 69.28K | 0.00 | 45.71K | 0.00 | 52.38K | 41.81K | 7.24K | 122.00 | 654.00 |
| Depreciation & Amortization | 27.62K | 28.10K | 26.14K | 28.07K | 30.78K | 26.63K | 20.29K | 16.97K | 15.42K | 7.16K | 5.89K | 5.58K | 5.37K | 453.00 | 27.40K | -2.78K | 0.00 | 0.00 |
| EBITDA | -2.59M | -2.09M | -2.73M | -4.56M | -2.58M | -913.39K | -2.14M | -2.92M | -2.04M | -1.83M | -2.22M | -1.55M | -1.29M | -1.64M | -2.72M | -355.65K | -472.86K | -529.67K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -232.39% | -2,194.56% | -9,192.76% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.61M | -2.12M | -2.76M | -4.53M | -2.62M | -959.95K | -2.16M | -2.95M | -2.05M | -1.83M | -2.28M | -1.16M | -1.30M | -1.29M | -524.71K | -355.65K | -472.86K | -529.67K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -239.02% | -2,215.41% | -9,246.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -414.99K | -1.72M | -5.29M | -437.13K | -287.98K | -209.03K | -177.11K | -128.24K | -79.25K | -38.63K | -5.25M | -1.60M | 2.10K | -589.06K | -907.38K | -4.46K | -122.00 | -333.00 |
| Income Before Tax | -3.03M | -3.84M | -8.05M | -4.97M | -2.91M | -1.17M | -2.33M | -3.07M | -2.13M | -1.87M | -7.47M | -1.20M | -1.30M | -1.78M | -2.79M | -360.10K | -472.99K | -530.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -291.07% | -2,397.40% | -9,648.57% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.72M | 660.42K | 386.62K | 294.35K | 19.92K | 0.00 | 139.43K | 101.55K | 69.28K | 0.00 | 48.71K | 0.00 | 52.38K | 41.81K | 7.24K | 0.00 | 321.00 |
| Net Income | -3.03M | -5.56M | -8.71M | -5.36M | -3.20M | -1.17M | -2.33M | -3.07M | -2.13M | -1.87M | -7.47M | -1.20M | -1.30M | -1.78M | -2.79M | -360.10K | -472.99K | -530.32K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -291.07% | -2,397.40% | -9,648.57% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 1.03B | 974.31M | 877.61M | 848.65M | 835.59M | 816.87M | 791.39M | 744.28M | 685.84M | 662.49M | 616.31M | 596.14M | 572.71M | 401.59M | 504.12M | 499.73M | 411.63M | 329.50M |
| Weighted Avg Shares Out (Dil) | 1.03B | 974.31M | 877.61M | 848.65M | 835.59M | 816.87M | 791.39M | 744.28M | 685.84M | 662.49M | 616.31M | 596.14M | 572.71M | 401.59M | 504.12M | 499.73M | 411.63M | 329.50M |
Kraig Biocraft Laboratories Signs Pivotal MOU in Vietnam's Silk Production Capital
Kraig Labs(OTCQB:KBLB) MOU with Vietnam Sericulture Assn(VSA) & Lam Dong Agro-Forestry Res Exp Cntr(LAREC) to enhance and expand silk production in VNM
Kraig Biocraft Laboratories Targets Vertical Markets for its Spider Silk and Shares Planned Applications
ANN ARBOR, Mich., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company"), shares an update on near-term commercial applications and opportunities for recombinant spider silk as the Company prepares for expanding production in 2024. Spider...
Kraig Biocraft Laboratories Joins Vietnam Sericulture Association
ANN ARBOR, Mich., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), the biotechnology company focused on the development and commercialization of spider silk, today announces its Vietnamese subsidiary, Prodigy Textiles ("Prodigy"), has...
Kraig Biocraft Laboratories Announces Successful Production Test Utilizing a Two Strain Hybrid System
ANN ARBOR, Mich., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), the biotechnology company focused on the development and commercialization of spider silk, today announces that it has successfully completed the first...
Kraig Biocraft Laboratories Announces Early Start to Production Season with Successful Small Batch Delivery of Spider Silk
ANN ARBOR, Mich., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), the biotechnology company focused on the development and commercialization of spider silk, today announces the early start to the production season...
Kraig Biocraft Laboratories Prepares for Silk Production Season
ANN ARBOR, Mich., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), the biotechnology company focused on the development and commercialization of spider silk, today announced that its senior management team is en...
Kraig Biocraft Laboratories Strengthens Spider Silk Production Operations with Sericulture Experts from India
ANN ARBOR, Mich., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), the biotechnology company focused on the development and commercialization of spider silk, today announced its continued investment into building its world-class...
Kraig Biocraft Laboratories Announces Management Changes and Recalibration at Its Vietnam subsidiary, Prodigy Textiles, to Support Production of Spider Silk
ANN ARBOR, Mich., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), the biotechnology company focused on the development and commercialization of spider silk, today announced a shakeup of the management of its...
New Sericulture Experts Join Kraig Biocraft Laboratories, Bringing Extensive Experience Supporting Acceleration of Production Ramp-Up
ANN ARBOR, Mich., July 19, 2023 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), the biotechnology company focused on the development and commercialization of spider silk, announces today that it has filled two key researcher...
Challenge Testing of Kraig Biocraft Laboratories' Disease Resistant Silkworms Underway
Immunity enhanced silkworms provide licensing opportunities into the broader $14B1 silk industry
Source: https://incomestatements.info
Category: Stock Reports